Neuropace Ownership
| NPCE Stock | USD 11.24 0.55 5.14% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Neuropace |
Neuropace Stock Ownership Analysis
About 62.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.93. Neuropace had not issued any dividends in recent years. NeuroPace, Inc. operates as a medical device company in the United States. The company was incorporated in 1997 and is headquartered in Mountain View, California. Neuropace operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 187 people. To find out more about Neuropace contact Michael Favet at (650) 237-2700 or learn more at https://www.neuropace.com.Besides selling stocks to institutional investors, Neuropace also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Neuropace's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Neuropace's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Neuropace Quarterly Liabilities And Stockholders Equity |
|
Neuropace Insider Trades History
Roughly 3.0% of Neuropace are currently held by insiders. Unlike Neuropace's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Neuropace's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Neuropace's insider trades
Neuropace Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Neuropace is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Neuropace backward and forwards among themselves. Neuropace's institutional investor refers to the entity that pools money to purchase Neuropace's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-12-31 | 323 K | Fmr Inc | 2024-12-31 | 249.7 K | Northern Trust Corp | 2024-12-31 | 184.8 K | State Street Corp | 2024-12-31 | 148.3 K | Jane Street Group Llc | 2024-12-31 | 100.1 K | Renaissance Technologies Corp | 2024-12-31 | 86.3 K | Jpmorgan Chase & Co | 2024-12-31 | 64.8 K | Jacobs Levy Equity Management, Inc. | 2024-12-31 | 57.1 K | Gsa Capital Partners Llp | 2024-12-31 | 56.4 K | Kck Ltd | 2024-12-31 | 5.3 M | Orbimed Advisors, Llc | 2024-12-31 | 3.4 M |
Neuropace Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Neuropace insiders, such as employees or executives, is commonly permitted as long as it does not rely on Neuropace's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Neuropace insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Neuropace Outstanding Bonds
Neuropace issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Neuropace uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Neuropace bonds can be classified according to their maturity, which is the date when Neuropace has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US64128XAE04 Corp BondUS64128XAE04 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Neuropace Corporate Filings
F4 | 5th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 4th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 18th of February 2025 Other Reports | ViewVerify | |
| 11th of February 2025 Other Reports | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Neuropace is a strong investment it is important to analyze Neuropace's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Neuropace's future performance. For an informed investment choice regarding Neuropace Stock, refer to the following important reports:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neuropace. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Neuropace Stock refer to our How to Trade Neuropace Stock guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuropace. If investors know Neuropace will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuropace listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.93) | Revenue Per Share | Quarterly Revenue Growth 0.192 | Return On Assets | Return On Equity |
The market value of Neuropace is measured differently than its book value, which is the value of Neuropace that is recorded on the company's balance sheet. Investors also form their own opinion of Neuropace's value that differs from its market value or its book value, called intrinsic value, which is Neuropace's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuropace's market value can be influenced by many factors that don't directly affect Neuropace's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neuropace's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuropace is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuropace's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.